Scotch Plains, NJ, United States of America

Nelo R Rivera

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 80(Granted Patents)

Location History:

Scotch Plains, NJ (US) (2002)
Milford, NJ (US) (2016)
New Milford, NJ (US) (2003 - 2019)

Company Filing History:

5 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2002-2019

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10407702 - Biocatalytic transamination process (2019-09-10),

2. 9738915 - Biocatalytic transamination process (2017-08-22),

3. 9493400 - Process for preparing fluoroleucine alkyl esters (2016-11-15),

4. 8487093 - β-lactamase inhibitors (2013-07-16),

5. 7829699 - Process for the preparation of CGRP antagonist (2010-11-09),

6. 7495123 - Process for the preparation of enantiomerically enriched beta amino acid derivatives (2009-02-24),

7. 7468459 - Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation (2008-12-23),

8. 6646130 - Process to chiral integrin antagonist beta-amino acid intermediate (2003-11-11),

9. 6423845 - Process and intermediates to a tetrahydro-[1,8]- Naphthyridine (2002-07-23),

10. 6407241 - Process and intermediates for the preparation of imidazolidinone &agr;v integrin antagonists (2002-06-18),

Title: Nelo R Rivera: Innovator in Biocatalytic Processes

Introduction

Nelo R Rivera is a prominent inventor based in Scotch Plains, NJ (US), known for his significant contributions to the field of biocatalysis. With a total of 10 patents to his name, Rivera has made remarkable advancements in the preparation of asymmetric compounds, particularly in the context of cancer treatment.

Latest Patents

One of Rivera's latest patents is a biocatalytic transamination process. This novel process provides an efficient method for preparing asymmetric compounds using dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. This innovative approach can be utilized to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors, which may be beneficial for cancer treatment.

Career Highlights

Throughout his career, Nelo R Rivera has worked with notable companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His work in these organizations has allowed him to develop and refine his innovative processes, contributing to advancements in pharmaceutical research and development.

Collaborations

Rivera has collaborated with esteemed colleagues, including Yi Xiao and Nobuyoshi Yasuda. These partnerships have fostered a collaborative environment that has enhanced the development of his patented processes.

Conclusion

Nelo R Rivera's contributions to biocatalytic processes and his innovative patents highlight his role as a key figure in the field of pharmaceutical research. His work continues to pave the way for advancements in cancer treatment and asymmetric compound preparation.

This text is generated by artificial intelligence and may not be accurate.